Natalie Alysia Dales

USPTO Granted Patents = 28 (Patent Applications = 13)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 6.8

ph-index = 9

Forward Citations = 142(Granted Patents)

Location History:

Cambridge, MA (US) (2015)
Arlington, MA (US) (1999 - 2023)

Company Filing History:

Xenon Pharmaceuticals Inc.

patents

4 out of 850

Millennium Pharmaceuticals Limited

patents

4. 1 out of 5

Shionogi Bioresearch Corporation

patents

5. 1 out of 1

Shiongi Bioresearch Corp.

patent

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252482 - Pyrazolopyridine derivatives and uses thereof (2025-03-18),

2. 12172984 - Pyrazolopyridine derivatives and uses thereof (2024-12-24),

3. 11787785 - Pyrazolopyridine derivatives and uses thereof (2023-10-17),

4. 11672799 - 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions (2023-06-13),

5. 11566022 - 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2023-01-31),

6. 11229648 - 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions (2022-01-25),

7. 10758533 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2020-09-01),

8. 10654828 - Indole derivatives and uses thereof (2020-05-19),

9. 10633350 - Diphenyl derivatives and uses thereof (2020-04-28),

10. 10195196 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2019-02-05),

11. 9545404 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2017-01-17),

12. 9187426 - Organic compounds (2015-11-17),

13. 9040712 - Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions (2015-05-26),

14. 8729263 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2014-05-20),

15. 8501746 - Organic compounds (2013-08-06),

Title: Innovations in Hematology: The Patents of Natalie Alysia Dales

Introduction: Natalie Alysia Dales, an accomplished inventor based in Arlington, MA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 27 patents. Her pioneering work primarily focuses on the development of treatments for inherited blood disorders, showcasing her dedication to improving patient outcomes.

Latest Patents: Among her latest innovations are patents related to pyrazolopyridine derivatives. These compounds have been utilized to create pharmaceutical compositions aimed at reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels. Furthermore, her work is instrumental in inducing fetal hemoglobin (HbF) expression, which plays a critical role in treating various hemoglobinopathies, including sickle cell disease and beta-thalassemia.

Career Highlights: Throughout her career, Dales has been associated with renowned companies, including Novartis AG and Xenon Pharmaceuticals Inc. Her work within these institutions has allowed her to leverage cutting-edge research and collaborate with leading experts in the field.

Collaborations: Dales has worked alongside notable collaborators such as John Ryan Kerrigan and Zaihui Zhang. These partnerships have enriched her research endeavors and enhanced the impact of her contributions to the medical community.

Conclusion: With a strong foundation in pharmaceutical innovation and a focus on addressing critical health issues, Natalie Alysia Dales continues to be a driving force in the field of hematology. Her extensive patent portfolio reflects her commitment to advancing treatments for inherited blood disorders and improving the quality of life for countless patients.

This text is generated by artificial intelligence and may not be accurate.